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It is apparent therefore, that the number of fibroblasts within the interstitium has a profound effect on the alveolar structures. Although it is generally recognized that these fibroblasts have a limited life span, the precise signals within the interstitial microenvironment that control alveolar fibroblast replication, and thus the fibroblast population size, have not been elucidated.
Current concepts of the regulation of cell division suggest that besides controls intrinsic to the cell, cellular replication is modulated by exogenous growth factors, a class of molecules that instructs cells to synthesize DNA and divide (7) (8) (9) (10) . In this context, regulation of alveolar fibroblast replication likely depends upon the presence of growth factors within the local milieu.
One possible source of growth factors for the alveolar fibroblast is the alveolar macrophage. This (11) , and it resides in close anatomic relationship to the alveolar fibroblast. Mononuclear phagocytes are known to influence the replication rate of several types of cells. With regard to the bone marrow, mononuclear phagocytes secrete colonystimulating factor(s), glycoproteins capable of stimulating granulocyte-monocyte precursors to replicate (12) . In addition, during the immune response, mononuclear phagocytes release interleukin-1, a 15,000-dalton growth factor that has a role in T lymphocyte replication (13) . Moreover, mononuclear phagocytes are known to be capable of releasing soluble factor(s) that cause fibroblasts to increase their rate of replication (14) (15) (16) (17) (18) .
In light of these observations, the present study was designed to evaluate a role for the human alveolar macrophage as a source of a growth factor for human lung fibroblasts. The data demonstrate that a variety of stimuli induce human alveolar macrophages to release a growth factor for fibroblasts, and that this growth factor is distinct from other characterized growth factors.
METHODS

Fibroblast cultures
The normal human diploid fetal lung fibroblast strain, HFL-1 (American Type Culture Collection, Rockville, MD, CCL 153), previously frozen at passage 3 to 4, was used in all experiments unless otherwise noted. Before use, the fibroblasts were thawed and cultured on 100-mm tissue culture plates (Falcon Labware, Div. of Becton, Dickinson & Co., Cockeysville, MD) in Dulbecco's modified Eagle medium (DMEM,' Gibco Diagnostics Laboratories, Grand Is- land, NY), supplemented with 10% calf serum (Colorado Serum Co., Denver, CO) in an atmosphere of 10% C02, 90% air at 37°C. The fibroblasts were used for the growth factor assay between subcultivations 5 and 20. Media were changed every other day and the cells subcultivated once a week.
Growth factor assay
To evaluate growth factor production by alveolar macrophages, supernates from macrophages cultured under various conditions were examined for their ability to stimulate noncycling lung fibroblasts to replicate.
Establishment of cultures of noncycling fibroblasts. The term "noncycling" lung fibroblasts will be used throughout this study to 50 vol of DMEM before use; (e) IgG immune complexes, and (f) IgM-C3b immune complexes both prepared using ox erythrocytes and rabbit antibodies as previously described (22) . To stimulate macrophages to produce growth factor, all agents were used at optimal concentrations determined by construction of dose-response curves: Sepharose or immune complexes were added at a final concentration of 1% (vol/vol) to the macrophage incubation mixture; zymosan and S. albus were used at 5 X 107 particles/ml.
To determine the relative ability of various agents to stimulate alveolar macrophages to produce the growth factor, 106 macrophages/ml were incubated in suspension culture in noncycling medium at 37°C with Sepharose, zymosan S. albus, IgG immune complexes, or IgM C3b immune complexes, as described above; or allowed to attach to a tissue culture dish. After 4 h of macrophage incubation, supernates were assayed for growth factor activity. As a control, each stimulus was incubated in parallel under identical conditions without macrophages present and the resultant supernates were found to have no effect on fibroblast growth.
To clarify the role of the small amount of serum (0.4%) present in the noncycling medium used for the macrophage incubations with the various stimulating agents, the experiment described above was also carried out in DMEM without serum. After the 4-h macrophage incubation with the stimulating agent, resultant supernates were supplemented with serum to a final concentration of 0.4% before assay for growth factor activity.
Determination of kinetics of alveolar macrophage-derived growth factor release To determine the kinetics of growth factor release, alveolar macrophages (106/ml) were incubated in suspension cul- Gel filtration. To further purify the alveolar macrophage-derived growth factor the two adjacent fractions from the DEAE-cellulose column with maximum growth factor activity were chromatographed on a 700-ml bed vol column (Pharmacia Fine Chemicals, 5 X 60 cm, flow rate 8 ml/h) of Sephadex G-75 (Pharmacia Fine Chemicals), equilibrated in phosphate-buffered saline without calcium or magnesium, pH 7.4 (Gibco Laboratories). The column was calibrated with blue dextran, ovalbumin, chymotrypsinogen A, ribonuclease A, (all from Pharmacia Fine Chemicals); insulin and bacitracin, (Calbiochem-Behring Corp., American Hoechst Corp., La Jolla, CA). 75 fractions (10 ml each) were collected and assayed for growth factor activity as described above. Serial dilutions of the active fractions were performed to quantitate growth factor recovery.
Relationship of the alveolar macrophagederived growth factor to other characterized growth factors
To determine the relationship of partially purified alveolar macrophage-derived growth factor to partially purified platelet-derived growth factor (prepared as described by Vogel et al. [23] ) and fibroblast growth factor (Collaborative Research Inc., Waltham, MA), each of these factors was chromatographed on DEAE-cellulose in separate column runs. Each factor was detected by its growth-promoting activity for fibroblasts in a manner identical to that described above. The relationship of the macrophage factor to insulin and epidermal growth factor (Collaborative Research) was evaluated by molecular weight determined by gel filtration chromatography with Sephadex G-75. Insulin was detected by its optical density at 280 nm and epidermal growth factor was detected by its growth promoting activity for fibroblasts. Comparison with human growth hormone was carried out by radioimmunoassay using the method of Odell et al. (24) . The relationship to somatomedin A, somatomedin C, multiplication stimulating activity, and insulinlike growth factors I and II was assessed by radioreceptor assays using the methods of Moses et al. (25) and Rechler et al. (26) . The relationship to multiplication stimulating activity and somatomedin C was also assessed by radioimmunoassay by the method of Moses et al. (27) and Furlanetto et al. (28) , respectively. Comparison with interleukin-1 was carried out by testing alveolar macrophage-derived growth factor in a standard interleukin-1 mouse thymocyte assay (29) and by testing human blood monocyte interleukin-1 in the fibroblast growth assay. An interleukin-1 standard was prepared as described by Mizel et al. (30) ; supernates of lipopolysaccharide-stimulated adherent human blood monocytes were concentrated and chromatographed on Sephadex G-75 with the active fractions (apparent mol wt 15,000) identified by their ability to cause mouse thymocytes to synthesize DNA. The interleukin-1 standard had no interleukin-2 activity, as determined by the method of Gillis et al. (31) .
Effect of partially purified growth factor on fibroblast DNA synthesis To determine the effect of partially purified alveolar macrophage-derived growth factor on fibroblast DNA synthesis, an active fraction from the DEAE cellulose column was diluted 1:100 with noncycling medium containing [3H]-thymidine (2 uCi/ml, 6.7 Ci/mmol, New England Nuclear, Boston, MA) and placed on noncycling fibroblasts (3 x 105/ 35-mm dish). At several time points after growth factor addition, fibroblasts on replicate plates were evaluated for the incorporation of [3H] thymidine into acid precipitable counts, as previously described (32) . To correct for [3H]thymidine incorporation unrelated to growth factor addition, four control plates were assayed in parallel at each time point and this value (which ranged from 200±150 at 2 h to 1,000±125 at 24 h) was subtracted from the value determined with growth factor present.
Effect of partially purified alveolar macrophage-derived growth factor on fibroblast replication in serum-free medium (complementation test)
One useful system for classifying growth factors has been proposed by Stiles et al. (33) , who have described a complementation test that allows classification of a growth factor as either a "progression" factor (e.g., multiplication-stimulating activity) or a "competence" factor (e.g., fibroblast growth factor, platelet-derived growth factor), according to its position of action within the cell cycle. In this context, these investigators have suggested that fibroblasts require the presence of both a competence factor and a progression factor to replicate. To evaluate the alveolar macrophagederived growth factor in this regard, a complementation test was performed in which the alveolar macrophage-derived growth factor was paired with either a characterized competence factor or a characterized progression factor and the effect on fibroblast replication assessed. Serum-free conditions were used for this assay so that the effect of the growth factors of interest could be directly evaluated without the complex interactions of these growth factors with undetermined serum constituents.
To establish the complementation test, fibroblasts were removed from a tissue culture dish by brief incubation in trypsin (1 min, 22°C) and cultured at 105 cells/35-mm dish in noncycling media for 2 d. On days 3, 4, and 5, fibroblast cultures were washed three times with complementation test medium (DMEM containing 1 mg/ml bovine serum albumin [radioimmunoassay grade, Sigma Chemical]) and fresh complementation test medium was added. After this interval, no cell division was observed without subsequent addition of growth factors.
On day 5, the macrophage factor was added to the fibroblast cultures with either a progression factor (multiplication-stimulating activity, 2 ng/ml) or with a competence factor (either fibroblast growth factor, 2 ng/ml, or plateletderived growth factor, 0.1 U/ml). As negative controls, each factor was used alone to confirm that fibroblast replication did not occur. As a positive control, multiplication-stimulating activity was added to the serum-free fibroblast culture with either platelet-derived growth factor or fibroblast growth factor. In all cases, after growth factor addition, fibroblasts were incubated at 37°C for 3 Quantitation of alveolar macrophagederived growth factor
The amount of growth factor present in a sample was experimentally determined by defining the fibroblast growth response to a set of dilutions of that sample, using principles described by Burn et al. (35) . To quantitate the amount of growth factor in a sample, the maximum increase in fibroblast number for the sample was found and the reciprocal of the dilution of the sample resulting in one-half of this maximum increase in fibroblast number was taken to represent the relative quantity of growth factor present. The quantity of growth factor is presented with error bars derived from the 95% confidence limits of the one-half maximum growth response (a value derived from the 95% confidence limits of the straight line connecting the experimental values flanking the calculated midpoint). Statistical comparisons of the dose-response curves for different samples were performed using the Wilcoxon rank-order test, which weights each value on the dose-response curve equally.
RESULTS
Fibroblast growth in response to alveolar macrophage-derived growth factor. Alveolar macrophages from normal individuals incubated in suspension culture with opsonized Sepharose released an activity that increased the growth rate of noncycling human lung fibroblasts (Fig. 1) Although all of the cell preparations used for these studies were >93% macrophages, formal demonstration that the source of the growth factor was macrophages and not lymphocytes was provided by studies in which bronchoalveolar lavage cells were separated into adherent (macrophages) and nonadherent (lymphocytes) fractions. Supernates of macrophages incubated for 4 values similar to those obtained from unfractionated cells. In marked contrast, supernates from lymphocytes had no influence on fibroblast replication. Moreover when unfractionated bronchoalveolar lavage cells were incubated for 4 h in suspension culture in the presence of opsonized Sepharose, washed in noncycling medium, and then separated into macrophage and lymphocyte fractions, all of the growth-promoting activity during a subsequent 4-h culture of the two cellular fractions was found in the supernates of the macrophages. Thus, under these conditions, macrophages were the sole source of growth-promoting activity for fibroblasts (data not shown).
Quantitation of alveolar macrophage-derived growth factor. An estimate of the quantity of alveolar macrophage-derived growth factor in a sample was provided by the reciprocal of the dilution corresponding to onehalf of the maximum growth response for that sample (Fig. 2) (Fig. 3A) . In Dependence of growth factor release on the concentration of macrophages. An assessment of the dependence of growth factor release on the concentration of macrophages (stimulated with opsonized zymosan) revealed no detectable growth-promoting activity with <5 X 104 macrophages/ml (Fig. 3B) . Progressively more growth-promoting activity was detectable with increasing cell concentration up to 1-2 X 106 macrophages/ml; at this concentration, one-half of the maximum increase in fibroblast number occurred at a supernatant dilution of '-1:125, i.e., a relative activity of 125. Higher cell Ability of various agents to stimulate the release of alveolar macrophage-derived growth factor. Several agents were capable of stimulating alveolar macrophages to release the growth factor for fibroblasts, but the relative growth-promoting activity of the resultant supernates was different for different groups of agents ( macrophages maintained in suspension with: (c) opsonized Sepharose (SEPH), (d) opsonized zymosan (ZYM), (e) heatkilled S. albus (STAPH), (f) IgG-immune complexes (IgG), (g) IgM-complement-immune complexes (IgM), (h) macrophages allowed to attach to a plastic culture dish (SURF, surface). After a 4 h incubation at 37°C, supernates were placed on noncycling fibroblasts for 48 h and the relative amount of growth factor present was determined using the analysis outlined in the legend to Fig. 2. intermediate amount of growth factor release each with a relative activity of -25; and surface attachment resulted in the least amount of growth factor release with a relative activity of 5. In contrast, unstimulated macrophages did not release any growth factor. Rank-order analysis revealed the difference among groups was significant (P < 0.01, all comparisons). In addition, for each stimulating agent, alveolar macrophages released the same amount of growth factor when cultured in DMEM without serum, as when cultured in noncycling medium containing 0.4% serum, which suggests that serum was not required for growth factor release (data not shown).
Partial purification of the alveolar macrophage-derived growth factor. Partial purification of the growth factor was accomplished by anion exchange chromatography followed by gel filtration. Approximately 1 mg of protein from cultures of zymosan-stimulated macrophages was chromatographed on DEAE-cellulose. The growth-promoting activity for fibroblasts bound to the anion exchange resin at neutral pH with the major peak of activity eluting at -0.27.M NaCl (Fig. SA) . This peak contained 1.2 Ag protein and a total relative growth promoting activity of 105. Gel filtration of the major DEAE cellulose peak on Sephadex G-75 revealed one significant peak of fibroblast growth-promoting activity with an apparent molecular weight of 18,000; this peak contained 60 ng protein with a total relative growth promoting activity of 104. Thus, assuming a molecular weight of 18,000, the alveolar macrophage-derived growth factor appears to be active in the nanomolar to picomolar range. To exclude the possibility that the small amount of serum adsorbed to the zymosan was required for growth factor production, chromatography of 0.16 mg of secretory protein from macrophages stimulated in an entirely serum-free system by adherence to a tissue culture dish was carried out. This resulted in identical ion-exchange and gel-filtration peaks (data not shown).
During both ion-exchange and gel-filtration chromatography, undiluted column fractions were found with some fibroblast growth-promoting activity that was clearly distinct from the main peak of bioactivity. However, since these fractions contained <0.01% of the total recoverable growth factor activity and did not have reproducible elution profiles, they were not analyzed further.
Effect of partially purified macrophage-derived growth factor on fibroblast DNA synthesis. [3H]thymidine incorporation by fibroblasts in noncycling medium in the absence of growth factor was subtracted from each data point.
complementation test was performed to allow classification of the alveolar macrophage-derived growth factor as a competence or progression factor. This evaluation of the fibroblast growth response to partially purified macrophage derived growth factor required the use of a characterized progression factor (multiplication stimulating activity), as well as a characterized competence factor (platelet-derived growth factor or fibroblast growth factor). In this complementation test, none of the growth factors individually caused any increase in fibroblast replication rate (Fig. 7) . Moreover, when either platelet-derived growth factor or fibroblast growth factor was added to complementation medium containing multiplication-stimulating activity, at least a 40% in- above control with the macrophage factor plus fibroblast growth factor and 42% above control with the macrophage factor plus platelet derived growth factor (P < 0.001, both comparisons compared with control).
Thus, in this complementation test, the macrophagederived growth factor acted as a progression factor. The necessity of having both a competence factor and a progression factor in the test system used was confirmed by our observing no increase in fibroblast replication with a 10-fold increase in the concentration of fibroblast growth factor alone or platelet-derived growth factor alone, or a 10-fold increase in the concentration of multiplication stimulating activity together with several concentrations (10-1_10-6) of macrophage-derived growth factor (data not shown). Evaluation of DNA synthesis by fibroblasts in response to partially purified alveolar macrophage-derived growth factor provided further confirmation that the alveolar macrophage-derived growth factor was a progression factor. Different dilutions of partially purified macrophage-derived growth factor (10-2_ 10-7) were combined with platelet-derived growth factor (0.1 U/ml) in complementation test medium. Significant increases in [3H]thymidine incorporation were observed with the macrophage factor diluted up to 10-5 (24,000±1,100 dpm above control), with peak incorporation observed at a dilution of 10-3 (29,000±1,300 dpm above control; P < 0.01, all comparisons with controls; data not shown). Neither platelet-derived growth factor alone nor alveolar macrophage-derived growth factor alone caused any increase in [3H]thymidine incorporation above control (1,350±250 dpm). Similar results were obtained when fibroblasts were cultured with alveolar macrophagederived growth factor and fibroblast growth factor (2 ng/ml).
Relationship of alveolar macrophage-derived growth factor to other characterized growth factors. Comparison of the macrophage-derived growth factor with other characterized growth factors suggested that it was unique. The apparent molecular weight of the alveolar macrophage-derived growth factor (18,000) was clearly different from that of the insulin-somatomedin family of growth factors (5,000-8,000) (7), epidermal growth factor (5,000) (36) , and the forms of human colony-stimulating factor purified to homogeneity (40,000) (37) (Fig. 5B) . Fibroblast growth factor (15,000) (38) and platelet-derived growth factor (30,000) (39) were distinguished from the macrophage factor by DEAE cellulose chromatography which demonstrated that the macrophage factor eluted at 0.27 M NaCl, whereas fibroblast growth factor and platelet-derived growth factor eluted at the front (0.02 M NaCl) of the column (Fig. 5A ). In addition, both platelet-derived growth factor and fibroblast growth factor bound to carboxymethyl-cellulose, whereas macrophage-derived growth factor did not (data not shown).
Although human growth hormone cochromatographed with macrophage-derived growth factor durMacrophage Growth Factor 815 rLs IL ing both ion exchange and gel filtration, radioimmunoassay showed the partially purified macrophage factor to have no antigenic cross reactivity with human growth hormone. Radioimmunoassay also revealed the alveolar macrophage-derived growth factor to have no antigenic cross-reactivity to multiplication-stimulating activity or somatomedin C. Furthermore, radioreceptor assay demonstrated that the macrophage factor was not insulinlike growth factor I/somatomedin C or insulinlike growth factor II/somatomedin A/multiplication-stimulating activity.
Although the macrophage-derived growth factor for fibroblasts has a molecular weight similar to interleukin-i, and both bind to DEAE-cellulose, interleukin-1 elutes before 0.10 M NaCl, whereas the macrophagederived growth factor does not elute until 0.27 M NaCl (30) . In addition, interleukin-1 was inactive in the fibroblast growth assay used (Fig. 8A ) and the macrophage-derived growth factor was inactive in the standard interleukin-1 mouse thymocyte proliferation assay used (Fig. 8B) .
Comparison of alveolar macrophage-derived growth factor with the other previously described macrophage-derived growth factors for fibroblasts (from hu-IA. man blood monocytes as well as from guinea pig and mouse peritoneal macrophages) revealed some biochemical similarities. In common with the alveolar macrophage factor all were nondialyzable (14) (15) (16) (17) (18) , and where examined their biological activity was destroyed by boiling (15, 17) (data not shown). The guinea pig peritoneal macrophage factor elutes with two peaks of activity using gel filtration, one similar to the human alveolar factor at -10,000-15,000 daltons and a second at -40,000-60,000 daltons (18) . However, the elution pattern of the 15,000-dalton guinea pig factor using ion exchange chromatography has not been characterized. The murine peritoneal macrophage factor, like the alveolar factor, did not bind to carboxymethyl-cellulose, but it chromatographed in the void volume of a Sephadex G-100 column, which suggests a higher molecular weight (17) . Thus, the alveolar macrophage-derived growth factor shared some biochemical features in common with other macrophage derived-growth factors for fibroblasts, although it appeared to be distinct.
Growth of different alveolar fibroblast strains in response to partially purified macrophage-derived growth factor. Several strains of normal alveolar fi- broblasts in addition to HFL-1 were found to be responsive to the macrophage-derived growth factor. Evaluation of five strains in a complementation test with platelet-derived growth factor (0.1 U/ml) demonstrated that each alveolar fibroblast had its own characteristic dose-response curve to the macrophagederived growth factor (Fig. 9) . 48 h. The growth factor is released by alveolar macrophages rapidly following stimulation by particulates, immune complexes, or surface attachment. Partial purification reveals the factor to be a macromolecule of -18,000 daltons that stimulates fibroblast replication in the nanomolar to picomolar range, and that appears to be distinct from other characterized growth factors. Though unable to stimulate fibroblast replication by itself in serum-free conditions, the alveolar macrophage-derived growth factor can be classified as a progression factor, providing a growth-promoting signal to noncycling fibroblasts that is complementary to that provided by competence factors such as fibroblast growth factor and platelet-derived growth factor.
Mononuclear phagocyte control of cellular replication. Alveolar macrophage release of the growth factor for lung fibroblasts is one of several examples of the ability of mononuclear phagocytes to modulate cell replication by secreting growth promoting mediators. In this context, colony-stimulating factor(s) that cause granulocyte-monocyte precursors in the bone marrow to replicate are released by human blood monocytes (40) and alveolar macrophages (12) , as well as by murine peritoneal macrophages (41) . In addition, interleukin-1, a growth factor augmenting the replication rate of certain lymphocytes subpopulations, is released by human blood monocytes and alveolar macrophages from a variety of animal sources (42) (43) (44) (45) (46) (47) (15) have shown that although endotoxin, concanavalin A, zymosan, and surface adherence all result in mononuclear phagocyte release of a growth factor for fibroblasts, endotoxin and conconavalin A are far more effective than zymosan or adherence. Thus, the finding that various agents are differentially effective in promoting release of the alveolar macrophage-derived growth factor is consistent with substantial precedent concerning a hierarchy of macrophage mediator release in response to a variety of activating agents.
Kinetics of release of the alveolar macrophage-derived growth factor. After appropriate stimulation, alveolar macrophages rapidly release the growth factor for fibroblasts, with maximal levels seen within 3-4 h. This rapid release of the growth factor by human alveolar macrophages after stimulation is similar to that observed by de Lustro et al. (16) using human blood monocytes and by Leibovich and Ross (14) using guinea pig peritoneal macrophages. The absence of preformed active growth factor in alveolar macrophages coupled with rapid release of this mediator after appropriate macrophage stimulation suggests that it is stored as an inactive precursor that can be rapidly converted to an active form. Preliminary experiments using cycloheximide and actinomycin D suggest that the amount of growth factor released during the first 1-2 h after stimulation is not dependent on de novo RNA or protein synthesis. However, release of growth factor after this time appears to be dependent on both RNA and protein synthesis. In addition, it is known that many macrophage mediators other than growth factors for fibroblasts are also released in this time period after stimulation. For example, the growth factors, colony-stimulating factor (41) , and interleukin-1 (59), as well as the inflammatory mediators neutrophil chemotactic factor (22) , reactive oxidant species (56), lysosomal hydrolases (60), and prostaglandin E2 (61) Biological properties of the alveolar macrophagederived growth factor. Although the mechanism of action of growth factors is not known, one useful system for classifying growth factors is based on the dualcontrol model of the cell cycle proposed by Stiles et al. (33) . Many growth factors can be conveniently divided into two categories, competence factors and progression factors. Competence factors act early in the G1 phase of the cell cycle, rendering a cell competent for a variable number of hours to respond to progression factors, which act sometime later in G1 to promote cell replication (63) . In common with the insulinlike growth factor/somatomedin family of growth factors, the alveolar macrophage-derived growth factor for fibroblasts is a progression factor (33) .
As a general principle, fibroblast replication in tissue culture requires both a competence factor and a progression factor. In the context of the alveolar structures, a corollary of this principle is that initiation of lung fibroblast replication probably involves a competence factorlike signal in addition to the progression activity supplied by the macrophage-derived growth factor. The source of such a competence factor in the alveolar structures is unknown. One source may be another soluble mediator released by macrophages or other effector cells. Alternatively, competence may be conferred upon lung fibroblasts continuously by their interaction with the interstitial matrix in a manner similar to that suggested by Gospodarowicz and Ill (64) in relation to endothelial cell replication. If the interstitial matrix does play this role in providing competence, macrophage-derived growth factor release could be sufficient to initiate lung fibroblast replication within the alveolar structures.
For the alveolar macrophage-derived growth factor to act as progression factor it must interact with the fibroblast surface in some manner. In this context, most characterized progression factors recognize a single class (or two closely related classes) of surface receptors that appear to mediate their growth-promoting effect (65) . The ability of a growth factor to bind this receptor can be assessed by using a chick embryo fibroblast radioreceptor assay that uses a common receptor to recognize most characterized progression factors, which are in the insulinlike growth factor/somatomedin family of growth factors (66) . Surprisingly, although the alveolar macrophage-derived growth factor for fibroblasts acts as a progression factor, it has no affinity for this surface receptor. One possible explanation for this observation derives from the work of Clemmons et al. (67) , who demonstrated that human growth hormone can stimulate human lung fibroblasts to produce their own somatomedin C, which in turn stimulates fibroblast replication. In this context, the alveolar macrophage-derived growth factor may act as a progression factor by inducing fibroblasts to produce and release an endogenous progression factor.
Possible role of alveolar macrophage-derived growth factor in controlling the population size of fibroblasts within the alveolar structures. Available information suggests that under normal circumstances the rate of fibroblast replication within the alveolar structures is very low, implying that the net balance of growth regulatory signals present is not sufficient to promote fibroblast replication (68) . In this context, alveolar macrophages from normal individuals do not release detectable amounts of the growth factor for fibroblasts unless activated. However, in several interstitial lung disorders associated with inflammation of the alveolar structures and activated macrophages, there are marked local accumulations of fibroblasts, which suggests that fibroblast replication is occurring. For example, in oxygen toxicity both morphometric and autoradiographic studies have demonstrated large increases in fibroblast replication rate (69, 70) .
Current concepts of the pathogenesis of interstitial lung disorders suggest that the process begins with stimuli that lead to alveolar inflammation characterized by increased numbers of activated immune and inflammatory cells. Heppleston and Styles (71) first focused attention on macrophages activated by silica as an important constituent of the inflammatory milieu within the alveolar structures in silicosis. In this context, in idiopathic pulmonary fibrosis, a chronic, progressive form of interstitial fibrosis, there are large numbers of macrophages within the alveolar structures that have been activated by immune complexes (72) . Significantly, immune complexes cause alveolar macrophages to release the growth factor for fibroblasts, and preliminary studies of patients with idiopathic pulmonary fibrosis suggest that in most cases, alveolar macrophages from these individuals are spontaneously producing the growth factor for fibroblasts (73) . Thus, it is possible that in fibrotic lung disease associated with alveolar macrophage activation, release of the growth factor for fibroblasts may play a role in the expansion of the numbers of fibroblasts within the alveolar structures that characterizes these disorders.
